Behandling af svær astma med biologiske lægemidler hos børn og unge
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.
Bidragets oversatte titel | Biological drugs for treatment of children and adolescents with severe asthma |
---|---|
Originalsprog | Dansk |
Artikelnummer | V05180364 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 181 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 2019 |
- Adolescent, Anti-Asthmatic Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Asthma/drug therapy, Biological Products/therapeutic use, Child, Humans, Omalizumab, Quality of Life
Forskningsområder
Links
- https://ugeskriftet.dk/videnskab/behandling-af-svaer-astma-med-biologiske-laegemidler-hos-born-og-unge
Forlagets udgivne version
ID: 240953435